Genfit SA Sponsored ADR Stock

$4.45

5.95% yesterday

Nasdaq, Nov 25, 08:52 pm CET

ISIN

US3722791098

Symbol

GNFT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Genfit SA Sponsored ADR Stock price

$4.26

-11.04 72.15% 5Y

Nasdaq, Closing price Mon, Nov 25 2024

+0.06 1.45%

ISIN

US3722791098

Symbol

GNFT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$212.45m
Enterprise Value	$219.04m
P/E (TTM) P/E ratio	8.80
EV/Sales (TTM) EV/Sales	2.66
P/S ratio (TTM) P/S ratio	2.58
P/B ratio (TTM) P/B ratio	2.05
Revenue growth (TTM) Revenue growth	243.10%
Revenue (TTM) Revenue	$82.22m
EBIT (operating result TTM) EBIT	$17.52m
EPS (TTM) EPS	$0.48
P/E forward	40.81
P/S forward	2.15
EV/Sales forward	2.21
Short interest	0.13%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Genfit SA Sponsored ADR Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Genfit SA Sponsored ADR forecast:

7x Buy

100%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Genfit SA Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Genfit SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Jun '24		+/- %
Revenue	82 82	243% 243% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	20 20	16% 16% 24%
- Research and Development Expense	42 42	7% 7% 51%
EBITDA	19 19	148% 148% 23%
- Depreciation and Amortization	1.62 1.62	10% 10% 2%
EBIT (Operating Income) EBIT	18 18	142% 142% 21%
Net Profit	24 24	167% 167% 29%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Genfit SA Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

13 days ago

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 13, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today provided a corporate update ahead of The Liver Meeting 2024®2.

Neutral

GlobeNewsWire

●

19 days ago

GENFIT Reports Third Quarter 2024 Financial Information

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland); November 7, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of September 30, 2024 and revenue for the first nine months of 20241.

Neutral

GlobeNewsWire

●

2 months ago

GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the European Commission has conditionally approved Iqirvo®1 (elafibranor) 80mg tablets for the treatment of ...

More Genfit SA Sponsored ADR News

Company Profile

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.

Head office	France
CEO	Pascal Prigent
Employees	159
Founded	1999
Website	www.genfit.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now